Endo Announces Issuance of Vasostrict® Patent
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St rises as yields ease, Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Endo's (ENDP) Vasostrict Patent News Seen as 'Important Development' at Deutsche Bank
June 28, 2016 3:20 PM EDTDeutsche Bank maintained a Buy rating on Endo International plc (NASDAQ: ENDP) with a price target of $30. Earlier the company announced that one of its operating companies, Par Pharmaceutical, was issued a new patent relating to Vasostrict 20 units/mL. Analyst
Gregg Gilbert said this was an important development and could help protect a key franchise.
"Vasostrict is a ~$300mn drug (~8% of total revenue), and risk... More
Endo International (ENDP) Vasostrict IP Adds Few Years of Exclusivity - Leerink
June 28, 2016 2:17 PM EDTLeerink Partners analyst Jason Gerberry weighed in on Endo International plc (NASDAQ: ENDP) after the company received issuance of US patent #9,375,478, which according to the analyst, at a minimum adds a few year to the firm's Vasostrict exclusivity assumption. While the bull case includes possible major price revision and significantly longer exclusivity,... More
Endo Int'l (ENDP) Vasostrict Patent News Negativly Impacts the Short Thesis - Mizuho
June 28, 2016 1:23 PM EDTMizuho analyst Irina Koffler weighed in on Endo Int'l (NASDAQ: ENDP) after the company announced that Vasostrict patent (9,375,478) that expires in Jan 2035, and has been submitted to FDA's Orange Book.
Koffler notes the drug represents approximately $300M in revenues to Endo,... More
Endo Int'l (ENDP) Surges on New Vasostrict Patent
June 28, 2016 12:50 PM EDTEndo Int'l (NASDAQ: ENDP) is surging 17% after the company announced that one of its operating... More
